Sign inJoin waitlistJoin the waitlist

Apostolia Tsimberidou

Professor · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
Present

University of Texas M D Anderson Cancer Center
1998–2000
National and Kapodistrian University of Athens
1995–1998
Theagenion Cancer Hospital
1993–1995
G. Papanicolaou Hospital
1992–1993
Doctor of Medicine
1987–1991

Research

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American…
Journal of Molecular Diagnostics · 2017 · 1,704 citations
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Review · Journal of Clinical Oncology · 2018 · 748 citations
Review of precision cancer medicine: Evolution of the treatment paradigm
Review · Cancer Treatment Reviews · 2020 · First of 4 authors · Corresponding · 522 citations

David Hong
164 papers
Aung Naing
155 papers · 2 as a fellow
Siqing Fu
146 papers
Sarina Piha-Paul
135 papers
Razelle Kurzrock
124 papers
FJ
Filip Janku
111 papers
JW
Jennifer Wheler
86 papers
Funda Meric-Bernstam
84 papers
Vivek Subbiah
78 papers
GF
Gerald Falchook
75 papers
DK
Daniel Karp
63 papers
RZ
Ralph Zinner
41 papers

Clinical trials

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2022–2026
Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors
Principal investigator · Terminated · Phase 1, Phase 2
OBI Pharma, Inc
2019–2023
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
Principal investigator · Terminated · Phase 1, Phase 2
OBI Pharma, Inc
2018–2024
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
Principal investigator · Terminated · Phase 1, Phase 2
OBI Pharma, Inc
2018–2022